Name: Nuvalent (NUVL) CEO On The Future Of Cancer Treatments
Uploaded: 2024-06-17T16:12:50.008-05:00
Duration: 7 min 29 s
Description: Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655. The latest NUVL earnings report indicated an EPS of -$0.69.

Morning Movers

Opening Bell With Nicole Petallides

Morning Trade Live

Trading 360

Fast Market

Next Gen Investing

The Watch List

Market On Close

Market Overtime

Inside the Mind of a Trader

Your First Trade

The Wrap

Liz Ann Live

Schwab 2026 Outlook

<p>Sam Vadas takes traders beyond the headlines with a sharp focus on the macro drivers, sector rotations, and global forces shaping the day’s market action. From breaking down U.S. and international economic data to analyzing sector performance and cross-asset moves, Morning Trade Live delivers the context traders need to understand the “why” behind early trading activity.</p>

Daily insights for every investor

Schwab Network's Newsletters

<p>Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655. The latest NUVL earnings report indicated an EPS of -$0.69.</p>

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Expert commentary about top moving stocks, sectors, and commodities, along with CEO and analyst interviews.

Market News